LRP1 and Alzheimer disease: In conclusion, we uncovered an application of BMP9 for the treatment of AD in a transgenic model by targeting multiple key pathways, including Aβ clearance mediated by LRP1, tau hyperphosphorylation mediated by GSK3β, and neuroinflammation.